about
Conjugate Haemophilus influenzae type b vaccines for sickle cell diseaseConjugate Haemophilus influenzae type b vaccines for sickle cell diseaseNeutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic ReviewEffect of sublingual administration of interferon-alpha on the immune response to influenza vaccination in institutionalized elderly individualsGag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness lossNeonatal plasmacytoid dendritic cells (pDCs) display subset variation but can elicit potent anti-viral innate responsesVaccine Education of Medical Students: A Nationwide Cross-sectional Survey.Pandemic influenza (A/H1N1) vaccine uptake among French private general practitioners: a cross sectional study in 2010.Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.Predictive factors of cytomegalovirus seropositivity among pregnant women in Paris, FranceSuppression by thimerosal of ex-vivo CD4+ T cell response to influenza vaccine and induction of apoptosis in primary memory T cells.Should expectant mothers be vaccinated against flu? A safety review.[Pandemic and prepandemic H5N1 influenza vaccines: a 2009 update].Lessons from a French collaborative case-control study in cystic fibrosis patients during the 2009 A/H1N1 influenza pandemy.[Pregnancy: a high risk factor in influenza infection].Seasonal influenza vaccination of high-risk adults.Pandemic influenza A (H1N1) in pregnant women: impact of early diagnosis and antiviral treatment.French experience of 2009 A/H1N1v influenza in pregnant women.Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial.Determinants of non-vaccination against pandemic 2009 H1N1 influenza in pregnant women: a prospective cohort study.Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial.Determinants of refusal of A/H1N1 pandemic vaccination in a high risk population: a qualitative approach.Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients.Failure of the vaccination campaign against A(H1N1) influenza in pregnant women in France: results from a national survey.Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial.Low rate of pandemic A/H1N1 2009 influenza infection and lack of severe complication of vaccination in pregnant women: a prospective cohort study.Rhinoviruses as an underestimated cause of influenza-like illness in pregnancy during the 2009-2010 influenza pandemic.Longitudinal and integrative biomodeling of effector and memory immune compartments after inactivated influenza vaccination.Factors associated with vaccination for hepatitis B, pertussis, seasonal and pandemic influenza among French general practitioners: a 2010 survey.Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort.Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D studyCellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trialCryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era.Autoimmune diseases in HIV-infected patients: 52 cases and literature review.Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness.First-year results of the Global Influenza Hospital Surveillance Network: 2012-2013 Northern hemisphere influenza season.2012-2013 Seasonal influenza vaccine effectiveness against influenza hospitalizations: results from the global influenza hospital surveillance network.Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumorsClinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans.
P50
Q24186131-4C43A2CC-7DB2-4F66-B3A8-0D9E4C30F577Q24195046-0B6A2338-30A5-4B7E-9208-4363ED36F098Q26700078-355166B8-7142-460C-966C-478E72C6B12AQ28286173-5C1A8366-D2C2-4014-8B4C-EFA3D6A8EDFDQ28474984-3E913B47-2A26-4631-8DF2-463A79FC2425Q28710009-B6BAC04A-9364-4E0B-9F40-47A5108B3BF0Q30151313-7486AE7B-05A0-4587-ACA4-7080B534E170Q30224500-DBA52BAE-B07B-46AA-832D-F53AEDFC6EB6Q30353675-241F242C-3D89-4E91-8A92-0CD599085872Q30354497-0D08E8CC-A81B-44BF-90DB-86859BAEB5D7Q30359694-6D088DD3-1158-433A-B4C2-830D5FEB942EQ30360878-815CD369-A01D-455B-B86E-1CD8D3B2302AQ30368344-0D6B2236-AC96-4C7B-93B2-74511CDF7567Q30380848-AC9C0D0D-FE11-4471-A69A-C40762E53C15Q30384047-5C77B9E3-D747-4F97-BF66-B58C312A82CCQ30385377-3EE3AB12-43CA-4628-964B-D980CF8D8135Q30387979-146834BE-938F-4B7C-8AC9-D65A99BB030AQ30393341-EFECC4DF-17B6-456F-BE4E-EFF6654FADD8Q30395018-78AD6192-74B8-4682-B31C-75F253D9E6A6Q30403299-E201E419-C5D6-48A9-A663-A39275BCF855Q30404091-D7087A88-2738-436F-A144-D95E85157BE7Q30410357-C232DCFA-635D-470D-BC36-F95B5C28F4CEQ30415411-A6A66255-86EC-46E7-8234-335DA427A7FFQ30417302-9214738F-DAD0-47F0-893A-B3DCBA6E5B31Q30419036-DAD1CF66-8FC9-41CF-9B2B-173C5DF37E39Q30419564-775C8928-2DAC-4C96-8DC4-BDFE5E40B73AQ30425675-F338D0E9-3BCF-4E86-98F2-9B0437A65396Q30431275-E52282A7-8E3A-4E73-B629-F046B14FF87CQ30432067-CD11A2CA-049D-4B50-8D73-7595643B132FQ30432490-97AC3448-DF06-4AC1-99B0-9EF42A3E481EQ30888876-25A3F46A-F0C1-4E5B-A4B0-D0A4F4F4F1D9Q33272469-BDC54D32-3BDD-4C0F-8DB7-175581EB4CA3Q33294821-D1A31536-8221-44FE-BCFA-41E4FB61EB70Q33328474-7D2E75F4-5DCB-49E6-A3BD-0778F38808F2Q33414717-273AD8C7-0D5E-47E8-95EC-0D74121602F7Q33684340-D2579004-2950-4463-9409-06DDEEFC9D13Q33756162-AAEE394F-72CB-4BE7-B6AA-E49EB422056FQ33779681-48C7D7D2-3338-492C-BDBF-0E0E1B998442Q33862822-B45F40CD-B96F-4483-A642-D54E58F35966Q34271609-B71FAD93-4321-4133-9258-568098454307
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
Odile Launay
@ast
Odile Launay
@en
Odile Launay
@es
Odile Launay
@nl
type
label
Odile Launay
@ast
Odile Launay
@en
Odile Launay
@es
Odile Launay
@nl
altLabel
Launay O
@en
Launay O.
@en
Launay
@en
O Launay
@en
O. Launay
@en
prefLabel
Odile Launay
@ast
Odile Launay
@en
Odile Launay
@es
Odile Launay
@nl
P31
P496
0000-0003-3242-7247